Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06302348 · ClinicalTrials.gov registry record · Phase 3
A Study of Sepiapterin in Participants With Phenylketonuria (PKU)
A Phase 3 study of Phenylketonuria, sponsored by PTC Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT06302348 is a Phase 3 study of Phenylketonuria that is actively recruiting participants, run by PTC Therapeutics. The registered enrollment target is 56 participants, below the 94-participant average among 12 other Phenylketonuria trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06302348, a Phase 3 study of Phenylketonuria, is actively recruiting participants, sponsored by PTC Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this trial is to evaluate the long-term efficacy of sepiapterin on preserving neurocognitive functioning in children with PKU when treatment is initiated in early childhood.
Conditions Studied
Interventions
- DRUG Sepiapterin
Study Locations (1)
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2024-03-04 |
| Est. Completion | 2031-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06302348
The ClinicalTrials.gov registry entry for NCT06302348 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 94-participant average among 12 other Phenylketonuria trials with a reported enrollment target (40% lower). The listed sponsor is PTC Therapeutics, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Phenylketonuria appearing as the primary indexed condition, and to 1 intervention - of which Sepiapterin is the first listed.
NCT06302348 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT06302348 about?
NCT06302348 is a clinical study titled "A Study of Sepiapterin in Participants With Phenylketonuria (PKU)". The main purpose of this trial is to evaluate the long-term efficacy of sepiapterin on preserving neurocognitive functioning in children with PKU when treatment is initiated in early childhood.
What is the current status of trial NCT06302348?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 56 participants. The study started on 2024-03-04. Estimated completion is 2031-02-28.
What conditions does trial NCT06302348 study?
This clinical trial studies the following conditions: Phenylketonuria.
What interventions are being tested in trial NCT06302348?
The interventions under investigation include: Sepiapterin (DRUG).
Who is sponsoring clinical trial NCT06302348?
This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06302348 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Phenylketonuria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety and Efficacy of JNT-517 in Participants With Phenylketonuria (PKU)
RECRUITING · Phase 3
-
A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients
COMPLETED · Phase 3
-
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
COMPLETED · Phase 3
-
Educational, Social Support, and Nutritional Interventions and Their Cumulative Effect on Pregnancy Outcomes and Quality of Life in Teen and Adult Women With Phenylketonuria
RECRUITING · NA
-
Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.